KRAS & NRAS Mutation Panel – Tumor Tissue Analysis – 2,400 AED

Executive Summary & Core Metrics

Our DHA-licensed laboratory (Facility #1143) delivers a highly sensitive KRAS & NRAS mutation panel using gold-standard Sanger sequencing from archival tumor tissue. This test guides anti-EGFR therapy decisions in colorectal cancer with 99.9% diagnostic accuracy. Secure medical courier retrieval of FFPE blocks or biopsy slides ensures specimen integrity. Post-test telephonic clinical guidance is provided at no extra cost. Insurance direct billing is available via WhatsApp +971 54 548 8731.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval (no home phlebotomy).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

Our KRAS & NRAS Mutation Panel uses high-fidelity Sanger sequencing to detect clinically significant mutations in codons 12, 13, and 61 of both genes. This targeted analysis provides definitive guidance for anti-EGFR therapy eligibility in colorectal cancer and offers prognostic insights for ovarian and endometrial malignancies.

Feature	Our KRAS & NRAS Panel	Generic NGS Panel
Precision	Gold‑standard Sanger sequencing with 99.9% analytical sensitivity and 100% specificity for hotspot regions.	Next‑generation sequencing; may show reduced coverage for KRAS/NRAS hotspots.
Method	Direct capillary electrophoresis sequencing (validated per ISO 9001:2015).	Parallel sequencing with bioinformatic analysis.
Turnaround Time	7–8 days	14–21 days
UAE Compliance	DHA Licensed Facility #1143, ISO 9001:2015, PDPL compliant.	May lack local DHA licensing.

Physician Insight & Safety Protocols

"As a radiologist, I understand the weight that genetic test results carry. This KRAS/NRAS panel is a powerful tool, but it must be interpreted within the full clinical context. Please never discontinue a prescribed medication without first consulting your treating physician."

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA ID 61713011

Medication Advisory: Do Not Self-Alter Therapy

⚠ Critical Alert

Do not discontinue or modify any prescribed anticancer or supportive therapy based solely on test results without explicit instruction from your oncologist.

Patient Safety Exclusion Criteria & ER Red Flags

Insufficient tumor tissue (inadequate FFPE block or biopsy material).
Inability to provide informed consent; for minors, guardian consent is mandatory as per UAE medical liability law (Federal Decree-Law No. 4 of 2016).
If you experience acute severe pain, uncontrolled bleeding, or signs of anaphylaxis after biopsy, seek emergency care immediately. This test does not replace acute clinical assessment.

Patient FAQ & Clinical Guidance

1. What is the KRAS & NRAS Mutation Panel used for?

This test detects mutations in KRAS and NRAS genes to determine eligibility for anti-EGFR targeted therapy in colorectal cancer. It also provides prognostic information for ovarian and endometrial cancers.

2. How is the sample collected, and is it painful?

The test requires an existing tumor tissue specimen (FFPE block, biopsy slide, or surgical resection) retrieved from the hospital or pathology archive. No new tissue collection is needed unless insufficient material exists. Collection is painless as it uses archived tissue.

3. Do I need a doctor's prescription, and can insurance cover it?

A valid DHA-licensed doctor’s prescription is required, except for surgery, pregnancy, or travel clearance cases per UAE regulations. Most major insurance plans are accepted; direct billing verification is available via WhatsApp +971 54 548 8731.

UAE Regulatory & Data Privacy Adherence

Data Protection & Healthcare Governance

This test is performed under the regulatory oversight of the Dubai Health Authority (Facility License 1143). All patient data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your results are encrypted and accessible only to authorized medical personnel.

Clinical & Logistical Metadata

Test Name	KRAS & NRAS Mutation Panel (Tumor Tissue)
Price (AED)	2,400 AED
Turnaround Time	7–8 business days
Sample Type / Matrix	Archival Tumor Tissue (FFPE block, biopsy slides, or surgical pathology cuts) – Secure Medical Courier Solid Tissue Specimen Retrieval
Methodology Used	Sanger Sequencing (capillary electrophoresis) – Codons 12, 13, 61
ICD-10-CM Code	C18.9 (Malignant neoplasm of colon, unspecified)
LOINC Code	94774-9 (RAS panel [Identifier] in Tissue)
DHA Facility License & Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE)